Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the World<\/p>\n
CAMBRIDGE, Mass. and ROSTOCK and BERLIN, Germany and SOUTH SAN FRANCISCO, Cal. – October 06, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Corporation (Nasdaq: TWST), a Company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today that they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases. The resulting products will be designed to make genetic testing more accessible to patients and further drive the understanding of rare diseases. Financial details were not disclosed.<\/p>\n
\u201cWe are excited to be working together with Twist as we seek to enable the most timely diagnosis for rare disease patients around the world,\u201d said Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. \u201cNot only will this help to provide patients with quicker and more comprehensive answers today, but it will generate insights to advance the precision medicine of tomorrow.\u201d<\/p>\n
The product offering will combine CENTOGENE\u2019s rare disease diagnostic expertise powered by the world\u2019s largest Bio\/Databank of its kind with Twist Bioscience\u2019s library preparation and target enrichment capabilities to deliver multiple assays for rare disease diagnosis and analysis. The aim is to increase genetic testing options for the one in 15 individuals that are diagnosed with a rare disease each year. Additionally, the insights generated through these products will augment the Bio\/Databank on rare diseases and may contribute to the discovery and development of novel therapeutics to treat rare diseases in the future.<\/p>\n
\u201cTwist continues to deliver science-driven tools to enable the accurate identification of rare diseases,\u201d said Emily M. Leproust, Ph.D., CEO and Co-Founder of Twist Bioscience. \u201cWe look forward to combining our robust NGS tools with CENTOGENE\u2019s rare disease insights to truly deliver advanced solutions for research professionals globally.\u201d<\/p>\n
This agreement represents another significant step forward for CENTOGENE\u2019s mission to drive novel insights and enable the cure of 100 rare diseases within the next 10 years.<\/p>\n
Dowiedz si\u0119 wi\u0119cej<\/a><\/p>\n Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by \u201cwriting\u201d DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.<\/p>\n Obserwuj nas na \u015awiergot<\/a> | Facebook<\/a> | Linkedin<\/a> | YouTube<\/a><\/p>\n CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne, genetyczne i multiomiczne w celu diagnozowania, zrozumienia i leczenia chor\u00f3b rzadkich. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych poprzez wykorzystanie naszej rozleg\u0142ej wiedzy i danych na temat chor\u00f3b rzadkich. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 bada\u0144 nad chorobami rzadkimi opart\u0105 na naszym repozytorium danych z rzeczywistego \u015bwiata, zawieraj\u0105cym ponad 3,9 miliarda wa\u017conych punkt\u00f3w danych od oko\u0142o 600 000 pacjent\u00f3w z ponad 120 kraj\u00f3w.<\/p>\n Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi pacjent\u00f3w i kultur kom\u00f3rkowych. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma skoncentrowana na kompleksowej analizie danych wielopoziomowych w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych. Umo\u017cliwia ona lepsz\u0105 identyfikacj\u0119 i stratyfikacj\u0119 pacjent\u00f3w oraz ich chor\u00f3b podstawowych, co umo\u017cliwia i przyspiesza odkrywanie, rozw\u00f3j i dost\u0119p do lek\u00f3w sierocych. Na dzie\u0144 31 grudnia 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z ponad 30 partnerami farmaceutycznymi.<\/p>\n Obserwuj nas na Linkedin<\/a> | \u015awiergot<\/a> | Facebook<\/a> | Instagram<\/a><\/p>\n This press release contains \u201cforward-looking statements\u201d within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature, including but not limited to statements relating to the collaboration between CENTOGENE and Twist are forward-looking, and the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinues,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cproject,\u201d and similar expressions and future or conditional verbs such as \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201ccan,\u201d and \u201cmay,\u201d are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE\u2019s or Twist\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties relating to CENTOGENE include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on its business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in its industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, its reliance on third parties and collaboration partners, including its ability to manage growth and enter into new client relationships, its dependency on the rare disease industry, its ability to manage international expansion, its reliance on key personnel, its reliance on intellectual property protection, fluctuations of its operating results due to the effect of exchange rates, or other factors. Such risks and uncertainties relating to Twist include, among others, the risks and uncertainties of the duration, extent and impact of the COVID-19 pandemic, including any reductions in demand for its products (or deferred or canceled orders) globally or in certain regions; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist\u2019s patents or proprietary rights; and the risk that Twist\u2019s proprietary rights may be insufficient to protect its technologies. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE\u2019s business and Twist\u2019s business in general, see CENTOGENE\u2019s risk factors set forth in CENTOGENE\u2019s Form 20-F filed on April 15, 2021, with the Securities and Exchange Commission (the \u201cSEC\u201d) and see Twist\u2019s risk factors set forth in Twist\u2019s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2021, respectively, and any subsequent filings by CENTOGENE or Twist with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, each of CENTOGENE and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.<\/p>\n CENTOGENE<\/p>\n Ben Legg Lennart Streibel Doradztwo FTI Rachel Kleiman Twist Bioscience<\/p>\nAbout Twist Bioscience Corporation<\/h2>\n
O firmie CENTOGENE<\/h4>\n
O\u015bwiadczenia prognostyczne<\/h4>\n
Kontakt dla medi\u00f3w:<\/h5>\n
Komunikacja korporacyjna
Ben.Legg@centogene.com<\/a><\/p>\n
Relacje inwestorskie
Investor.Relations@centogene.com<\/a><\/p>\n
Robert Stanislaro
robert.stanislaro@fticonsulting.com<\/a> <\/p>\n
rachel.kleiman@fticonsulting.com<\/a><\/p>\n